Welcome to our dedicated page for Clover Health Investments news (Ticker: CLOV), a resource for investors and traders seeking the latest updates and insights on Clover Health Investments stock.
Clover Health Investments, Corp. reports developments in physician enablement technology and Medicare Advantage insurance. The company offers PPO and HMO Medicare Advantage plans and uses its Clover Assistant software platform to aggregate patient data, support clinical decision-making, and address chronic disease management for Medicare populations.
Recurring Clover Health news includes quarterly and annual results, Medicare Advantage membership trends, medical cost and profitability metrics, and guidance updates. Company updates also cover Counterpart Health, the subsidiary that extends the data-driven physician enablement platform beyond Clover’s Medicare Advantage plan, including interoperability collaborations, patient data access, and clinical research tied to conditions such as diabetes, chronic kidney disease, congestive heart failure, COPD, and preventive care.
Clover Health (Nasdaq: CLOV) has announced its participation in two major upcoming investor conferences in March 2025. Chief Financial Officer Peter Kuipers will be representing the company at both events.
The first engagement is at the 2025 Jefferies Value-Based Healthcare Summit on Monday, March 10, 2025. Following this, Kuipers will present at the 2025 Leerink Global Healthcare Conference on Tuesday, March 11, 2025, at 8:00 a.m. Eastern Time.
For interested parties, a live webcast and replay of the Leerink conference presentation and Q&A session will be available through Clover Health's investor relations website at investors.cloverhealth.com.
Clover Health (NASDAQ: CLOV) has announced it will release its fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the results.
Interested parties can access the call by dialing 800-274-8461 (U.S. callers) or 203-518-9814 (international callers) using the conference ID: CLOVQ424. A live and archived webcast will be available on Clover Health's Investor Relations website for 12 months.
Counterpart Health, a subsidiary of Clover Health (NASDAQ: CLOV), has announced a multi-year strategic partnership with Southern Illinois Healthcare (SIH), the largest health system in Southern Illinois. The agreement centers on implementing Counterpart Assistant, an AI-powered platform integrated into SIH's EPIC electronic health record system.
The platform will provide real-time, patient-specific insights to physicians, supporting value-based care delivery without adding administrative complexity. SIH's care teams will receive actionable, data-driven insights directly within their workflows, enabling better patient outcomes while meeting value-based care metrics.
The partnership aims to enhance clinical decision-making, facilitate earlier diagnoses, and improve chronic disease management. Counterpart Assistant, previously known as Clover Assistant, has demonstrated success in improving medication adherence and managing conditions like Diabetes and Chronic Kidney Disease.
Clover Health (CLOV) reported a significant 27% year-over-year growth in its Medicare Advantage membership, surpassing 100,000 members after the recent Annual Election Period. Approximately 95% of members are enrolled in the company's flagship 4-Star PPO plan.
The growth was primarily driven by members switching from other plans, attracted by Clover's robust plan benefits. The 4-Star rating positions the company for an anticipated 5% benchmark increase in payment year 2026. Clover emphasizes its technology-driven approach, using AI to improve clinical outcomes through early identification and management of chronic diseases.
The company plans to balance profitability with strategic investments in growth and technology, leveraging its strong market position and integrated care model. The 4-Star PPO plan has demonstrated top performance across key HEDIS measures, reflecting Clover's commitment to healthcare quality.
Counterpart Health, a subsidiary of Clover Health (NASDAQ: CLOV), has successfully deployed its Counterpart Assistant technology at Duke Connected Care (DCC). The AI-powered physician enablement platform is now being used by primary care physicians across DCC's network of non-employed physicians.
The cloud-based AI platform integrates with existing electronic health record systems to provide real-time, actionable insights for improved chronic disease management and patient outcomes. DCC, part of Duke University Health System, is a physician-led accountable care organization supporting 2,200 providers and 200,000 patients.
The implementation aims to unify and optimize performance across DCC's network of community practices, particularly benefiting small rural practices that may not have access to advanced EHR systems. The technology, previously known as Clover Assistant, has demonstrated positive impacts on Clinical Quality, Medication Adherence, and management of Diabetes and Chronic Kidney Disease.
Clover Health (Nasdaq: CLOV) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO Andrew Toy will deliver a presentation on Wednesday, January 15, 2025, at 4:30 p.m. Eastern Time. Investors and interested parties can access both the live webcast and replay of the presentation and Q&A session through Clover Health's investor relations website at investors.cloverhealth.com.
Clover Health (NASDAQ: CLOV) reported strong Q3 2024 results with significant improvements in financial performance. Insurance revenue grew 7% year-over-year to $322.6 million in Q3, and 9% to $1.0 billion year-to-date. The company reduced its GAAP Net loss from continuing operations to $8.8 million from $33.6 million in Q3 2023, while Adjusted EBITDA increased to $19.3 million from $2.7 million. Insurance BER improved to 82.8% in Q3 2024. Based on strong performance, Clover Health raised its full-year 2024 Adjusted EBITDA guidance to $55-65 million.
Clover Health (Nasdaq: CLOV) has announced its participation in several upcoming investor conferences in November and December 2024. CFO Peter Kuipers will present at the UBS Global Healthcare Conference on November 12 at 5:00 p.m. ET and the Citi Global Healthcare Conference on December 3 at 3:15 p.m. ET. He will also participate in the Canaccord Genuity Medical Technology Forum on November 21. CEO Andrew Toy will join the Virtual BTIG Digital Health Forum on November 25. Live webcasts and replays of the fireside chat presentations will be available on Clover Health's investor relations website.
Clover Health (Nasdaq: CLOV) announced it will release its third quarter 2024 financial results after market close on Wednesday, November 6, 2024. The company will host a conference call and webcast at 5:00 p.m. Eastern Time the same day to discuss the results. U.S. participants can dial 800-579-2543, while international callers should use 785-424-1789, with conference ID CLOVQ324. The webcast will be available on Clover Health's Investor Relations website for 12 months.
Clover Health (Nasdaq: CLOV) has unveiled its 2025 Medicare Advantage (MA) plan offerings in New Jersey, focusing on affordable and flexible healthcare options for seniors. The company's flagship PPO plans, which serve over 95% of its MA membership, have received a 4 Star rating from CMS. Clover's 2025 plans include:
- Low specialist and prescription drug copays
- Enhanced OTC and dental allowances
- A rewards program offering up to $400 annually for healthy activities
- Competitive in-network and out-of-network costs for PPO plans
CEO Jamie Reynoso emphasized Clover's commitment to providing stability and increased value for members, especially during a time when many plans are scaling back benefits. The company aims to help New Jersey seniors manage their healthcare costs while maintaining quality and affordability.